Riskpilot← Back to searchSign inGet full accessBackaplan Vårdcentral AB
ABActiveOrg 5590453634Gamla Tuvevägen 23General medical practice activities · NACE 8621Est. 20165-9 employees
Revenue 2025
SEK 6,7M
-2% vs 2024
EBITDA margin
6.0%
+80% vs 2024
Equity ratio
43.0%
Financial strength
Net profit 2025
SEK 402K
+86% vs 2024
| Revenue | SEK 6,7M | -2% |
| EBITDA | SEK 403K | +80% |
| Net profit | SEK 402K | +86% |
| Total assets | SEK 2M | +32% |
| Equity | SEK 854K | +89% |
| Employees | — | — |
Legal name
Backaplan Vårdcentral AB
Org number
5590453634
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
3 januari 2016
Share capital
SEK 50 000
Employees
5-9
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet skall vara primärvårds- mottagningar även specialistläkarverksamhet inom öppenvård samt därmed förenlig verksamhet.
Address
Gamla Tuvevägen 23
Email
aajoct@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 053 | 8 382 | 6 677 | 6 887 | 6 719 |
| Staff expenses | — | −6 415 | −4 924 | −5 084 | −4 824 |
| EBITDA | 859 | 29 | 197 | 224 | 403 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 859 | 29 | 197 | 224 | 403 |
| Net financials | −16 | −5 | −15 | −8 | −1 |
| Profit before tax | 843 | 24 | 182 | 216 | 402 |
| Tax | −0 | — | — | — | — |
| Net profit | 843 | 24 | 182 | 216 | 402 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 788 | 2 006 | 1 453 | 1 509 | 1 985 |
| Equity | 29 | 53 | 235 | 451 | 854 |
| Long-term debt | 506 | 498 | 502 | 473 | 471 |
| Short-term debt | 1 253 | 1 455 | 715 | 585 | 661 |
| Total debt | 1 759 | 1 953 | 1 217 | 1 058 | 1 131 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20212025
Equity ratio
43.0%
This company
38.2%
Market median
+13% vs market
20212025
Return on equity
47.1%
This company
18.4%
Market median
+156% vs market
20212025
Net profit margin
6.0%
This company
8.1%
Market median
-26% vs market
20212025
Asset turnover
3.39×
This company
1.12×
Market median
+203% vs market
20212025
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HJ | Audit | 2023 |
AA Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2021 | |
| Chairman | 2026 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Backaplan Vårdcentral AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Jimmy Störkersen | Audit | 0 companies |
| Amir Alfio Jafari | Chief Executive Officer | 0 companies |
| Methal Abdulrazzak Kadhem | Deputy Board Member | 0 companies |
| Nils Erik Thomas Planhage | Deputy Board Member | 0 companies |
| Jamshid Jalouli | Chairman | 0 companies |
| Elina Mehnosh Jafari | Board of Directors | 0 companies |